Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Guanylate kinase 1 is an essential cytoplasmic enzyme that catalyzes the phosphorylation of guanosine monophosphate (GMP) to guanosine diphosphate (GDP) using ATP. It is the principal enzyme responsible for maintaining the balance of nucleotide pools required for DNA and RNA synthesis, cell proliferation, and cell survival. Guanylate kinase 1 also plays a critical role in the metabolic activation of several nucleoside analog prodrugs used in the treatment of cancer and viral infections, such as 6-thioguanine, 6-mercaptopurine, ganciclovir, and acyclovir. Functional loss or inhibition of this enzyme disrupts nucleotide homeostasis and can impair cancer cell viability. Structure-function studies show that human guanylate kinase consists of three domains—LID, GMP-binding, and CORE domains. Its pharmacological relevance makes it an emerging target for anticancer and antiviral therapy.
Prodrug activation: catalyzes phosphorylation of nucleoside analogs for antineoplastic and antiviral effect
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Guanylate kinase 1 (GUK1).